CoChat

Tapering of SSRI treatment to mitigate withdrawal symptoms

Open access
Horowitz, Mark Abie, Taylor, David · 2019 · The Lancet Psychiatry

The DOI matches its Crossref record; 76 of the 81 references it cites were found in a registry or an index; 27 of the 104 sources its claims cite were checked for support.

Abstract

All classes of drug that are prescribed to treat depression are associated with withdrawal syndromes. SSRI withdrawal syndrome occurs often and can be severe, and might compel patients to recommence their medication. Although the withdrawal syndrome can be differentiated from recurrence of the underlying disorder, it might also be mistaken for recurrence, leading to long-term unnecessary medication. Guidelines recommend short tapers, of between 2 weeks and 4 weeks, down to therapeutic minimum doses, or half-minimum doses, before complete cessation. Studies have shown that these tapers show minimal benefits over abrupt discontinuation, and are often not tolerated by patients. Tapers over a period of months and down to doses much lower than minimum therapeutic doses have shown greater success in reducing withdrawal symptoms. Other types of medication associated with withdrawal, such as benzodiazepenes, are tapered to reduce their biological effect at receptors by fixed amounts to minimise withdrawal symptoms. These dose reductions are done with exponential tapering programmes that reach very small doses. This method could have relevance for tapering of SSRIs. We examined the PET imaging data of serotonin transporter occupancy by SSRIs and found that hyperbolically reducing doses of SSRIs reduces their effect on serotonin transporter inhibition in a linear manner. We therefore suggest that SSRIs should be tapered hyperbolically and slowly to doses much lower than those of therapeutic minimums, in line with tapering regimens for other medications associated with withdrawal symptoms. Withdrawal symptoms will then be minimised.

Overview

CoChat Summary

TL;DR

This review argues that SSRI withdrawal is common and that current 2–4 week linear tapers are often ineffective, and it proposes hyperbolic tapering based on PET-derived serotonin transporter (SERT) occupancy. By reducing dose in fixed steps of biological effect—e.g., approximately 10% SERT occupancy—withdrawal symptoms should be minimized.

Key findings

  • SSRI withdrawal incidence varies widely: paroxetine 42–100%, fluoxetine 9–77%, and a median of 53.6% across 14 studies; the 14-day discontinuation period was associated with a 60% increase in suicide attempts compared with previous antidepressant users.
  • Short tapers of 2–4 weeks show no or minimal benefit over abrupt discontinuation, whereas longer tapers perform better: paroxetine reduced by 10 mg every 2 weeks lowered withdrawal incidence from 34% to 4.6%; tapering up to 4 months produced 5.1 vs 11.7 DESS events; an average 38.6-week paroxetine taper had 6% vs 78% withdrawal with abrupt discontinuation; tapering strips allowed 71% of 1194 patients to discontinue over a median of 2 months.
  • PET SERT occupancy data show a hyperbolic dose-response, so linear dose reductions cause increasingly large drops in SERT inhibition. For citalopram, 5 mg decrements from 20 mg produce SERT inhibition decreases of 3% (20→15 mg), 6% (15→10 mg), 13% (10→5 mg), and 58% (5→0 mg); even 2.5 mg→0 mg produces a 42.9% reduction and 1.25 mg→0 mg a 28% reduction, larger than 40 mg→5 mg (27.3%).
  • The proposed hyperbolic regimen reduces dose by fixed intervals of biological effect, such as 10% SERT occupancy steps; for citalopram this gives 20, 9.1, 5.4, 3.4, 2.3, 1.5, 0.8, 0.37, 0 mg, with a final dose near 10% SERT occupancy. Fluoxetine may allow approximately 30% SERT occupancy steps and a three-month observation period because of its long half-life.

Methods

  • Narrative review/hypothesis paper; no new primary clinical trial or patient sample is reported.
  • It synthesizes existing literature on SSRI withdrawal and tapering and uses PET imaging data of SERT occupancy by SSRIs, applying law-of-mass-action/Michaelis-Menten modeling to the dose-response relationship.
  • Main analysis derives hyperbolic tapering schedules and practical recommendations, including an initial test reduction, DESS monitoring, and individualization of taper rate.

Limitations

  • Stated: the PET study had relatively few participants, limiting capture of individual variation; other SSRI targets beyond SERT exist though are thought downstream; it is difficult to determine whether SERT inhibition linearly corresponds to withdrawal effects, and a threshold effect is theoretically possible; striatal SERT occupancy may not directly reflect antidepressant action.
  • Stated: the optimal interval between dose reductions and the timing of neuroadaptation are not established; recommendations are based on clinical experience/consensus and require randomized controlled trial confirmation.
  • Evident: the proposed hyperbolic taper is not prospectively tested in this paper, and no direct clinical outcome data are presented for the specific regimen; the argument relies on secondary data and pharmacological modeling.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1016/s2215-0366(19)30032-x

Cites

76 of 76 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

13 Valid · 12 Not valid · 33 Not checked · 24 Own results and interpretations

48 more claims · 9 with their cited sources checked

Create a free account to see all 82 claims and to verify the 1 reference still open.

See all claims — free account
  • It may state two separate claims as one. 24
  • Probably not a substantial claim. 8

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

26 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Citations

Cites

Show all 76 references

Cited by

See all 280

Metadata

Authors
Horowitz, M. A., & Taylor, D.
Affiliations
  • Prince of Wales Hospital (AU)
  • King's College London (GB)
Corresponding author
Horowitz, Mark Abie
Venue
The Lancet Psychiatry
Publisher
Elsevier BV
Published
2019-06
Volume
6
Issue
6
Pages
538-546
ISSN
2215-0366 (ISSN-L)
OpenAlex
W2919124707
Cited by
280
References
81
Citations by year
2026: 45 · 2025: 37 · 2024: 44 · 2023: 40 · 2022: 35 · 2021: 32 · 2020: 32 · 2019: 15
FWCI
3.65
Type
journal article
Language
en
Open access
Licence
  • other-oa
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)
Locations
  • The Lancet Psychiatry (publishedVersion)
  • PubMed (publishedVersion)
  • Research Portal (King's College London) (acceptedVersion, other-oa)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
  • Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
Keywords
selective serotonin reuptake inhibitors, medication tapering, positron emission tomography, depression, benzodiazepine withdrawal, dose reduction, antidepressant discontinuation
MeSH terms
Dose-Response Relationship, Drug, Humans, Substance Withdrawal Syndrome, Selective Serotonin Reuptake Inhibitors, Practice Guidelines as Topic, Positron-Emission Tomography, Serotonin Plasma Membrane Transport Proteins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Tapering of SSRI treatment to mitigate withdrawal symptoms. https://app.cochat.ai/papers/10.1016/s2215-0366(19)30032-x
The paper
Horowitz, M. A., & Taylor, D. (2019). Tapering of SSRI treatment to mitigate withdrawal symptoms. The Lancet Psychiatry. https://doi.org/10.1016/s2215-0366(19)30032-x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.